RxDoctor Payments Data

Meenal Dwyer, MD

Family Medicine · Newport News, VANPI 1740387521

Payments from drug & device makers

$8,854in general payments, 2019–2025

Across 527 payments — averaging $16.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$764
  • Lilly USA, LLC$547
  • Boehringer Ingelheim$387
  • GSK$376
  • plus $4K from 49 others

What the payments were for

  • Food & beverage$8,848100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)98$1,386
Novo Nordisk57$1,090
AstraZeneca48$764
Lilly USA, LLC34$547
Boehringer Ingelheim22$387
GSK24$376
Amgen24$368
Pfizer21$361
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$352
Takeda Pharmaceuticals U.S.A., Inc.18$280
Amarin Pharma, Inc.14$247
Biohaven Pharmaceuticals, Inc.10$199
Axsome Therapeutics, Inc.3$167
Johnson & Johnson11$165
Teva Pharmaceuticals USA, Inc.7$146
Antares Pharma, Inc.7$132
Merck8$125
Clarus Therapeutics Inc.9$115
Tolmar, Inc.7$115
Ironshore Pharmaceuticals Inc.3$111
Astellas Pharma US Inc6$111
Exact Sciences5$107
Supernus Pharmaceuticals, Inc.5$98
Sanofi-aventis U.S. LLC6$96
Jazz Pharmaceuticals Inc.5$84
Mylan Specialty L.p.6$76
Bausch Health US, LLC4$67
Arbor Pharmaceuticals, Inc.3$63
Shire North American Group Inc4$62
Upsher-smith Laboratories LLC2$47
Paratek Pharmaceuticals, Inc.2$36
Phadia US Inc.2$35
Esperion Therapeutics, Inc.2$34
Kaleo, Inc.2$33
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$32
Boston Scientific1$32
Neos Therapeutics, LP2$31
Nestle Healthcare Nutrition Inc.2$30
Kowa Pharmaceuticals America, Inc.2$30
ARS Pharmaceuticals Operations, Inc.1$27
Aytu Biopharma, Inc.2$25
Organon1$25
Sumitomo Pharma America, Inc.1$24
Biohaven Pharmaceutical Holding Company Ltd.1$23
Otsuka America Pharmaceutical, Inc.1$23
Azurity Pharmaceuticals, Inc.1$20
Almatica Pharma LLC1$20
Philips North America LLC1$18
Genentech USA, Inc.1$18
Abbott1$17
Agios Pharmaceuticals, Inc.1$17
E.r. Squibb & Sons, L.L.C.1$17
Amneal Pharmaceuticals LLC1$16
Xeris Pharmaceuticals, Inc.1$14
Metuchen Pharmaceuticals1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,854 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$214,283
Medicare patients
422
Services billed
5,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide57$100,054
JardianceEmpagliflozin70$88,986
TrulicityDulaglutide42$76,562
EliquisApixaban80$68,632
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$36,114
FarxigaDapagliflozin Propanediol17$28,596
XareltoRivaroxaban19$26,100
JanuviaSitagliptin Phosphate16$25,437
MounjaroTirzepatide14$19,456
Nurtec OdtRimegepant Sulfate13$19,021
Stiolto RespimatTiotropium Br/Olodaterol Hcl16$18,401
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$16,731
Janumet XrSitagliptin Phos/Metformin Hcl11$13,081
MyrbetriqMirabegron11$10,018
Breo ElliptaFluticasone/Vilanterol14$9,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$387$107,38786 claims
Novo NordiskOzempic$1,090$100,05457 claims
Lilly USA, LLCTrulicity, Mounjaro$547$96,01856 claims
PfizerEliquis, Nurtec Odt$361$87,65393 claims
MerckJanuvia, Janumet Xr$125$38,51827 claims
AstraZenecaFarxiga, Symbicort$764$33,08430 claims
GSKTrelegy Ellipta, Breo Ellipta$376$26,38626 claims
Johnson & JohnsonXarelto$165$26,10019 claims
Astellas Pharma US IncMyrbetriq$111$10,01811 claims
AbbVieSynthroid$1,386$4,45260 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$3,430293 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →